This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to ope…

Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer

~Estimated

~$10 – $7,500

Hoffmann-La RocheNCT04802759

Phase 2

Phase II Trial Of Fulvestrant Plus Abemaciclib In Er-Positive, Her2-Negative Metastatic Breast Cancer Immediately After Failure Of A Cdk4/6 Inhibitor

The study will investigate if CDK4/6 inhibitor holiday will reset the cell cycle process to respond to the combination of fulvestrant and abemaciclib, and this…

ER-Positive Breast CancerHER2-negative Breast Cancer

~Estimated

~$10 – $6,250

The Methodist Hospital Research InstituteNCT05305924